Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Efimosfermin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on Efimosfermin alfa, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
8 min read
HDAC3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
LM-299 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on LM-299, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
8 min read
HDAC2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
BDTX-4933 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on BDTX-4933, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
8 min read
HDAC1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HCN4 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HCN4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HCN2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HCN2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Felzartamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on Felzartamab, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
Latest Hotspot
8 min read
Gamgertamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on Gamgertamig, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
Latest Hotspot
8 min read
XNW-27011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
A 2026 licensing due diligence report on XNW-27011, using PatSnap MCP data to assess asset status, clinical evidence, IP signals, transactions, risks, and a go/no-go recommendation.
8 min read
HCN1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HCN1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.